Loading
A phase 2 trial of atezolizumab in lung cancer, run by British Columbia Cancer Agency, now recruiting.
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity is a phase 2, interventional study registered as NCT04273061 by British Columbia Cancer Agency, with a registry enrolment figure of 50 participants, started 2020-06-17 and due to reach its primary completion in 2027-10. Interventions recorded: Atezolizumab. Conditions listed: Breast Cancer; Lung Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Gynecologic Cancer; Sarcoma; Unknown Primary Tumors; Head and Neck Cancer; Skin Cancer. Primary outcome: Overall response rate (ORR) for the study cohort, as defined by RECIST 1.1. Sites: Canada. No results are recorded here; the registry entry is the source.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.